|By PR Newswire||
|November 6, 2012 07:31 AM EST||
CASTLE ROCK, Colo.,, Nov. 6, 2012 /PRNewswire/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an in vitro diagnostic company, today announced it has engaged Miquel Vernet to consult with the Company as it prepares for European commercialization. Mr. Vernet will work closely with Don Hurd, Chief Commercial Officer of AspenBio. AspenBio anticipates obtaining CE Mark for its appendicitis diagnostic test before the end of the year, followed by a commercial launch in major European territories.
Steve Lundy, President and CEO of AspenBio, stated, "We are very excited Miquel has agreed to assist us in advance of our anticipated European launch. Miquel is a highly experienced sales and marketing professional. Previously, while I was at GeneOhm Sciences, I handpicked him to lead our European commercial efforts and he was instrumental in some of our successes there. Having Miquel's assistance is a critical step as AspenBio assembles its distribution network in Europe prior to obtaining CE Mark, which we expect to announce later this quarter."
About AspenBio Pharma
AspenBio Pharma, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The unique appendicitis test has projected high sensitivity and negative predictive value and is designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The test is being developed initially for pediatric, adolescent and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. For more information, visit www.aspenbiopharma.com.
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for the appendicitis test required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from the appendicitis test, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Final Prospectus filed on June 20, 2012.
SOURCE AspenBio Pharma, Inc.